Ultragenyx ($RARE) Stock Hub: GENGLYCOS Approved, a Priority Review Voucher Issued and UX111 Due September 19

01 Q2 2026: the operating picture improved, but the catalyst risk did not disappear

Ultragenyx reported record second-quarter revenue of $214 million, up about 28% from $167 million a year earlier. Crysvita contributed $156 million, Dojolvi $27 million, Evkeeza $21 million and Mepsevii $10 million. Net loss narrowed to $92 million, or $0.90 per share, from $115 million, or $1.17 per share. Cash, cash equivalents and marketable securities ended June at $436 million, while quarterly operating cash use fell to $97 million.

The company reaffirmed 2026 revenue guidance of $730–760 million, excluding any sales from potential new launches, and maintained its target of reaching profitability in 2027. With GENGLYCOS approved on August 19, the dated events still ahead are UX111 on September 19 and GTX-102 Phase 3 data in the September–October window, alongside the commercial execution of a first gene-therapy launch.

02 Executive Summary

Ultragenyx is a commercial-stage rare-disease company rather than a single-asset biotech. That distinction matters after the failure of setrusumab in osteogenesis imperfecta: the program damaged confidence and removed a potentially important growth asset, but it did not eliminate a four-product revenue base or the remaining late-stage pipeline. Q2 2026 reinforces that point. The company produced its highest quarterly revenue, lowered the quarterly operating cash burn versus the prior-year period and narrowed its net loss.

The stronger quarter does not de-risk the three events that now determine the next valuation step. DTX401 received accelerated approval as GENGLYCOS on August 19, 2026 in glycogen storage disease type Ia, which converts that event from a review risk into a launch and post-marketing question. UX111, resubmitted after a 2025 Complete Response Letter tied to CMC and facility/process observations, has a September 19 PDUFA in Sanfilippo syndrome type A. GTX-102, now called apazunersen, has Phase 3 Aspire data expected in September or October in Angelman syndrome.

The base case is therefore more balanced than the headline “record revenue” suggests. The commercial business is scaling and the 2027 profitability target remains alive, but the company still has $289 million of quarterly operating expenses, a $291 million stockholders’ deficit and substantial manufacturing, regulatory and launch-execution exposure. The next two months can validate the platform, delay it or split the outcome between commercial strength and pipeline uncertainty.

What the quarter settles and what it does not: Q2 improves the floor under the story, not the ceiling. A durable re-rating still requires clean regulatory execution and credible GTX-102 data. Revenue growth alone cannot fully offset a failed PDUFA or an ambiguous pivotal readout.

03 Q2 2026 Financial Results

Quarterly revenue comparison

Revenue increased faster than operating expenses, which helped reduce the operating loss. The quarter is directionally consistent with management’s profitability goal, although it does not by itself establish a sustainable break-even trajectory.

Guidance

• Total 2026 revenue: $730–760 million, excluding revenue from potential DTX401 or UX111 launches.
• Crysvita: $500–520 million.
• Dojolvi: $100–110 million.
• 2026 combined R&D and SG&A: flat to down low-single digits versus 2025.
• 2027 combined R&D and SG&A: expected to decline by at least 15% versus 2025.
• Profitability: management continues to target 2027.

The exclusion of potential new-launch revenue is useful: approval-related upside is not required to hit the existing revenue range. It does not mean approvals would create immediate large sales, however. Rare-disease gene-therapy launches require patient identification, treatment-center readiness, payer authorization and manufacturing execution.

04 Commercial Portfolio

Crysvita

Crysvita remains the economic anchor. Q2 revenue rose about 29% year over year to $156 million, including $54 million of product sales in Latin America and Türkiye, $94 million of U.S. and Canadian royalty revenue and $8 million of European royalty revenue. The product supports the commercial platform, but investors must distinguish reported revenue from the cash economics retained after prior royalty-financing transactions.

Dojolvi

Dojolvi revenue increased to $27 million. The product was added to Japan’s National Health Insurance drug-price list and launched there in May 2026 after receiving conditional manufacturing and marketing approval in March. The Japan expansion broadens the franchise but is unlikely to dominate the near-term stock reaction compared with the gene-therapy decisions.

Generic entry now has a date. On August 7, 2026 Ultragenyx and Baylor Research Institute settled the patent litigation brought against Esjay Pharma over its abbreviated new drug application for a generic version of Dojolvi. Under the settlement Esjay receives a non-exclusive, royalty-free licence to market its generic from January 1, 2033, extended to July 1, 2033 if paediatric exclusivity is granted for Dojolvi, subject to customary conditions. Similar cases against other ANDA filers remain pending in the District of New Jersey, and the agreement goes to the Federal Trade Commission and the Department of Justice as the law requires. Source: Form 8-K reporting the August 7, 2026 agreement, filed August 11, 2026.

Evkeeza and Mepsevii

Evkeeza grew 50% from a smaller base to $21 million, driven by country launches and early access. Mepsevii generated $10 million. Together, these products demonstrate that Ultragenyx can use a global rare-disease commercial infrastructure across assets, but neither currently changes the central catalyst dependence.

05 The Setrusumab Reset

Setrusumab, or UX143, failed the primary fracture-rate endpoints in the Phase 3 Orbit and Cosmic studies in osteogenesis imperfecta. Improvements in bone mineral density did not compensate for the primary-endpoint miss. The failure removed a major pipeline opportunity, led to the curtailment of manufacturing activity and contributed to the February 2026 restructuring.

The correct interpretation is not that the whole company failed. It is that the burden of proof increased. DTX401, UX111 and GTX-102 now need to be assessed on their own clinical, regulatory and manufacturing merits rather than being valued as interchangeable “shots on goal.”

Persistent red flag: Rare-disease biology and high unmet need do not guarantee pivotal success. Endpoint relevance, manufacturing quality, safety durability and regulatory acceptance must be evaluated separately for every program.

06 DTX401: Accelerated Approval as GENGLYCOS

DTX401, now marketed as GENGLYCOS, pariglasgene brecaparvovec-opnr, is an AAV8 gene therapy for glycogen storage disease type Ia. The disorder is caused by G6PC deficiency and requires intensive dietary management, including frequent cornstarch administration, to reduce the risk of severe hypoglycemia. On August 19, 2026 the FDA granted accelerated approval in adult and pediatric patients eight years and older, four days ahead of the August 23 action date, and the company filed the announcement the same day under Item 8.01 of a Form 8-K.

The approval rests on the Phase 3 GlucoGene study: 48 weeks, randomised, double-blind and placebo-controlled, 46 participants aged eight and older treated with DTX401 at 1.0 x 10^13 GC/kg or placebo, with a reduction in cornstarch requirement in the treated group at p<0.001. The modified intention-to-treat population used for the Week 48 efficacy analysis counted 44 participants, 20 on DTX401 and 24 on placebo. Eligible participants crossed over at Week 48 and continued to be followed, with analyses at Week 96 and Week 144.

Accelerated approval carries obligations. Ultragenyx has agreed to provide two years of safety and efficacy data from open-label commercial treatment of 50 patients and 20 control patients, the controls being patients who sought commercial treatment but cannot receive GENGLYCOS because of anti-AAV8 antibodies, through an enhancement of its existing GSDIa Disease Monitoring Program. The programme will also follow previously treated trial participants, for a total of ten years of observation. The open questions move accordingly: confirmatory evidence, uptake against the anti-AAV8 antibody screen, pricing and reimbursement, and manufacturing supply for a commercial launch.

What the approval does not settle: An accelerated approval is granted on a surrogate or intermediate measure and remains subject to the confirmatory obligations described above. It converts a regulatory question into a launch and post-marketing one, it does not remove it.

07 UX111: September 19 PDUFA After a CRL

UX111, or rebisufligene etisparvovec, is an AAV9 gene therapy for Sanfilippo syndrome type A. The FDA issued a Complete Response Letter in July 2025 citing CMC and facility/process observations. Ultragenyx said the agency did not identify issues with the clinical package submitted at that time, although updated clinical data were requested for the resubmission.

The resubmitted BLA is under review with a September 19, 2026 target date. An approval would be medically important and would show that Ultragenyx resolved the manufacturing and process issues that blocked the first review. A second delay or CRL would be especially damaging because it would affect confidence in the company’s internal manufacturing capabilities beyond this single asset.

08 GTX-102 / Apazunersen: September–October Phase 3 Data

GTX-102 is an antisense oligonucleotide designed to unsilence the paternal UBE3A allele in neurons in Angelman syndrome. The sham-controlled Phase 3 Aspire study enrolled 129 patients with a full maternal UBE3A deletion and randomized them 1:1 to GTX-102 or sham.

The new Q2 guidance narrows the pivotal readout from the broad second half of 2026 to September or October. It is the most advanced programme among those without an approval. Positive, consistent and clinically meaningful results could rebuild confidence after setrusumab and add a potentially major CNS rare-disease franchise. Weak, mixed or endpoint-dependent results could erase part of the benefit from positive FDA decisions.

The Aurora Phase 2/3 study in other genotypes and age groups is expected to complete enrollment in the second half of 2026, supporting a broader development strategy if Aspire succeeds.

09 Other Pipeline Programs

UX701 in Wilson disease

Enrollment is complete in the fourth dose-finding cohort of the pivotal Cyprus2+ study. Data are expected in the fourth quarter of 2026. The optimized dose and immunomodulation regimen need to produce a clearer and more consistent response profile before the market can assign substantial late-stage value.

DTX301 in OTC deficiency

The Phase 3 Enh3ance study previously met its 36-week ammonia-exposure endpoint. Patients in the treatment and crossover groups are progressing through 64 weeks of follow-up. Data from the second primary endpoint—reduction in treatment burden, including ammonia-scavenger use and dietary management—are expected in the first half of 2027.

UX016 in GNE myopathy

The FDA has cleared the IND for this sialic-acid prodrug. An externally funded Phase 1/2 study is expected to begin in the second half of 2026. It is pipeline replenishment rather than a near-term valuation driver.

10 Liquidity, Burn and Dilution

Ultragenyx ended June with $436 million of cash, cash equivalents and marketable securities, down from $737 million at December 31. Q2 operating cash use was $97 million, an improvement from $108 million in Q2 2025 and substantially below the unusually heavy $197 million used in Q1 2026, which included annual bonuses and UX143-related manufacturing payments.

The balance-sheet headline remains mixed. Working capital was $255 million and stockholders’ deficit was $291 million at June 30. The company also has financing obligations linked to sales of future royalties, reflected in $22 million of non-cash royalty-liability interest expense during Q2. Royalty monetization has supplied non-dilutive capital but reduces future retained economics.

The weighted-average diluted share count used for Q2 loss-per-share calculations increased to 101.9 million from 98.5 million a year earlier, about 3.5%. This is not evidence of a new Q2 offering by itself, but it shows that per-share analysis must account for a gradually expanding share base. The full Form 10-Q should be used to verify current ATM capacity, quarter-specific issuance and all royalty obligations.

Runway interpretation: A simple $436M divided by $97M quarterly burn suggests more than four quarters of liquidity, but that is not a formal runway forecast. Launch spending, milestone receipts, PRV proceeds, trial timing, working-capital movements and financing activity can materially change the result.

11 2026–2027 Catalyst Timeline

12 Bull, Base and Bear Cases

Bull case

GENGLYCOS converts its August 19 approval into initial commercial treatment and UX111 clears the September 19 review, launch preparation converts into initial patient treatment without major manufacturing friction, and GTX-102 produces convincing pivotal data. Existing revenue continues to grow, potential voucher monetization supplies capital and the exclusion of new launches from guidance creates upside to the commercial base. In this scenario the 2027 profitability target becomes materially more credible.

Base case

The commercial portfolio remains strong, but regulatory and clinical outcomes are mixed. One gene therapy may be approved while the other is delayed or receives a restrictive label, and GTX-102 may be positive without immediately answering every regulatory question. RARE remains volatile and catalyst-driven while management works to reduce spending.

Bear case

A CMC or inspection issue disrupts one of the PDUFAs, GTX-102 fails to show a robust and consistent functional benefit, or launch costs keep the burn elevated. The cash balance then becomes a more immediate concern and the market discounts the remaining pipeline more aggressively after the setrusumab precedent.

13 Key Risks

• CMC and inspection risk: particularly important after the prior UX111 CRL.
• Binary regulatory concentration: one PDUFA falls four weeks after an approval already granted.
• CNS endpoint risk: Angelman outcomes can be heterogeneous and difficult to measure.
• Cash consumption: profitability remains a target, not an achieved state.
• Royalty financing: strengthens liquidity today while transferring part of future economics.
• Commercial execution: approvals do not guarantee rapid patient identification, payer access or treatment-center throughput.
• Share-count expansion: weighted-average shares rose year over year.
• Litigation and execution complexity: multiple products, manufacturing operations and trials increase operational burden.

14 What to Watch Next

On GENGLYCOS the signals that matter now are the label as published, pricing and reimbursement decisions, the first treated patients and how the anti-AAV8 antibody screen affects the eligible population. For UX111, investors should focus on whether management provides confidence that every CMC and facility observation behind the 2025 CRL has been addressed. For GTX-102, the relevant questions are effect size, consistency across functional domains, safety, durability and whether the primary analysis supports a clear regulatory path.

The next earnings report should be judged not only on revenue, but also on operating cash use, launch spending, any Priority Review Voucher plans, ATM activity, share count and progress toward the 2027 expense reductions.

15 Bottom Line

Ultragenyx delivered a materially stronger operating quarter: record revenue, a narrower loss and lower quarterly cash use. That gives the company a better foundation entering the most consequential stretch of its 2026 calendar. It does not remove the binary risk.

The calendar is concentrated in a few weeks. DTX401 tests the liver-directed AAV platform and launch readiness. UX111 tests whether Ultragenyx truly resolved the manufacturing problems behind its CRL. GTX-102 tests whether the company can convert promising long-term Angelman data into pivotal success. A positive sequence could rebuild the platform valuation; a mixed sequence could leave a growing commercial company trapped under a pipeline discount.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

16 Follow the next RARE catalysts

Receive new Merlintrader deep dives and verified market updates when they are published.

Join @merlintraderpub_com on Telegram
Disclaimer: This content is provided for informational and educational purposes only. It is not financial advice, investment research in a regulatory sense, a recommendation, a solicitation or an offer to buy or sell any security. Biotechnology stocks can be extremely volatile around FDA decisions, clinical data, manufacturing inspections, financing events and earnings. Readers are responsible for their own research and decisions.